Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel Retreatment in R/R LBCL
NCT05800067Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05800067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800067.